About this trial
The goal of this clinical trial is to compare intrathecal bupivacaine with or without morphine for postoperative analgesia in patients undergoing elective cesarean section. The main questions it aims to answer are:
Is intrathecal bupivacaine with morphine superior to intrathecal bupivacaine alone for postoperative analgesia for parturients undergoing cesarean section? What is the duration of analgesia in the two groups? Researchers will compare drug intrathecal bupivacaine with morphine to a iintrathecal bupivacaine alone to see if intrathecal morphine has benefits for psotoperative analgesia .
Participants will:
Get intrathecal bupivacaine with Morphine or intrathecal bupivacaine alone during spinal anesthesia for cesarean section.
They will be followed up for NRS pain scores and side effects for 24 hours. Time to need of first rescue analgesic will be noted
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Parturients undergoing elective caesarean section under Spinal anesthesia
ASA PS II, III
> 18 years
Disqualifiers
Refusal to Participate
Contraindications to spinal anaesthesia and adjuvants INR ≥ 1.5 Plateletes < 1,00,000/cumm Severe aortic stenosis, and/or severe mitral stenosis Infection at lumbar puncture site Known allergy to local anesthetics and opioids
Communication barrier
Height <150 cm
Trial design
Parallel
Treatments tested in this trial
Intrathecal morphine with bupivacaine
DrugParticipants will receive 100 mcg intrathecal morphine along with 2.2ml of 0.5% hyperbaric bupivacaine
Hyperbaric Bupivicaine
Drug0.5% hyperbaric Bupivacaine 2.2 ml
Treatment groups
Trial outcomes
Primary outcomes
Time to need of first rescue analgesic
time of spinal anesthesia to time of demand of first rescue analgesic
NRS score
comapre NRS score at 0,1,6,12,18,24 hours between the groups
Secondary outcomes
24 hours analgesic consumption
consumtion of total analgesic in first 24 hours
Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: